Xspray

Xspray Pharma AB is a pharmaceutical manufacturer specializing in the development of advanced cancer treatments, particularly improved protein kinase inhibitors (PKIs), utilizing its innovative, patented HyNap technology. The company focuses on creating best-in-class amorphous drug products by enhancing properties like solubility and uptake consistency for existing marketed PKIs. Xspray Pharma's product portfolio includes four key candidates: Dasynoc (dasatinib), Nilopki (nilotinib), XS008 (axitinib), and XS025 (cabozantinib), all aiming to improve upon established original drugs like Sprycel, Tasigna, Inlyta, and Cabometyx. Dasynoc, an improved version of Sprycel for chronic myeloid and acute lymphoblastic leukemia, is unaffected by stomach pH, allowing concurrent use with proton-pump inhibitors, and can be administered at a 30-percent lower dose. Nilopki, targeting chronic myeloid leukemia, offers matching bioavailability to Tasigna at a significantly reduced dose, with FDA market approval pending by June 18, 2026. XS008 axitinib and XS025 cabozantinib are being developed for kidney and other cancers, leveraging Xspray's platform to enhance efficacy and patient outcomes. The company's focus is on bringing these improved therapies to market, with the original drugs in its portfolio representing over USD 5.2 billion in annual US sales.